Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 11/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.33 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.33 |
| ▸ | ACACB | O00763 | 4/20 | 0.32 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20158765 | 0.89 | GRM2 (0.48) | GRM2CNR2PTGER4GRIN1GRIN2B | |
| SCHEMBL18164351 | 0.85 | GRM2 (0.37) | GRM2CNR2PTGER4GRIN1GRIN2B | |
| SCHEMBL23073274 | 0.82 | GRM2 (0.35) | GRM2CNR2ACACB | |
| SCHEMBL18152777 | 0.81 | GRM2 (0.34) | GRM2CNR2ACACBCNR1 | |
| SCHEMBL18164550 | 0.80 | CNR2 (0.36) | GRM2CNR2GRIN1GRIN2BACACB | |
| SCHEMBL23473109 | 0.80 | CNR2 (0.33) | GRM2CNR2GRIN1GRIN2BACACB | |
| SCHEMBL18226817 | 0.70 | GRM2 (0.43) | GRM2GRIN2B | |
| SCHEMBL18164393 | 0.70 | GRM2 (0.37) | GRM2CNR2 | |
| SCHEMBL15252373 | 0.69 | CDK4 (0.42) | GRM2CNR2PTGER4GRIN2BACACB | |
| SCHEMBL18164379 | 0.68 | GRM2 (0.36) | GRM2CNR2GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3831383-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3831383-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| EP-3283077-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3283077-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2021-03-10 | — | — | EP | disclosed |
| US-10807982-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-10807982-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-10-20 | — | — | US | disclosed |
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908885-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2016168682-A2 | BROMODOMAIN INHIBITOR | CELGENE QUANTICEL RESEARCH, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071332-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | GRM2 2764/4885CNR2 3909/4885PTGER4 3276/4885 |
| US-20170050968-A1 | BROMODOMAIN INHIBITOR | BRD3, BRPF3, EP300 | GRM2 2820/4885CNR2 3922/4885PTGER4 3332/4885 |
| US-10807982-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | GRM2 2764/4885CNR2 3909/4885PTGER4 3276/4885 |
| US-20180134710-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | GRM2 2764/4885CNR2 3909/4885PTGER4 3276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.